Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate Oncolytic replication-selective adenoviruses are a new class of anticancer agents with great therapeutic potential. The ability of replication-selective viruses to amplify the initial viral dose has been exploited by engineering oncolytic adenoviruses to deliver therapeutic transgenes. In this Exploration Award, we are testing the concept that an oncolytic adenovirus can be armed with a therapeutic gene that will exert a systemic effect in the treatment of breast cancer. Breast cancer most commonly metastasizes to the skeleton. Thus, a treatment that combines eradication of the primary tumor with inhibition of osteolytic bone metastases would be a highly beneficial addition to the therapeutic armamentarium. We hypothesize that an oncolytic adenovirus armed with the osteoprotegerin (OPG) gene would be able to eradicate a primary breast cancer tumor by oncolysis, and that secretion of OPG from the infected and lysed cells into the systemic circulation would inhibit osteolytic bone metastases of the breast cancer. Thus, we propose a new class of therapeutic agent for the treatment of breast cancer. To date, we have constructed a replication-defective adenoviral vector expressing human OPG fused with the Fc domain of human lgG, and have evaluated the efficacy of the armed replicating adenoviral vector in vitro.
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ABSTRACT (Maximum 200 Words)
Oncolytic replication-selective adenoviruses are a new class of anticancer agents with great therapeutic potential. The ability of replication-selective viruses to amplify the initial viral dose has been exploited by engineering oncolytic adenoviruses to deliver therapeutic transgenes. In this Exploration Award, we are testing the concept that an oncolytic adenovirus can be armed with a therapeutic gene that will exert a systemic effect in the treatment of breast cancer. Breast cancer most commonly metastasizes to the skeleton. Thus, a treatment that combines eradication of the primary tumor with inhibition of osteolytic bone metastases would be a highly beneficial addition to the therapeutic armamentarium. We hypothesize that an oncolytic adenovirus armed with the osteoprotegerin (OPG) gene would be able to eradicate a primary breast cancer tumor by oncolysis, and that secretion of OPG from the infected and lysed cells into the systemic circulation would inhibit osteolytic bone metastases of the breast cancer. Thus, we propose a new class of therapeutic agent for the treatment of breast cancer. 
INTRODUCTION
Oncolytic replication-selective adenoviruses are a new class of anticancer agents with great therapeutic potential. The selective replication of the viruses in cancer cells amplifies the initial viral inoculum, leading to destruction of the infected cells by virus-mediated lysis. The viral progeny are thereby released and can spread through the tumor mass to infect neighboring cancer cells, resulting in self-perpetuating cycles of infection, replication and oncolysis. The ability of replication-selective viruses to amplify the initial viral dose has been exploited by engineering oncolytic adenoviruses to deliver therapeutic transgenes. To date, such "armed" oncolytic adenoviruses have been designed to carry therapeutic genes that will augment the virus-mediated eradication of the primary tumor mass. Replication-competent adenoviruses have been shown to yield levels of transgene expression up to three orders of magnitude greater than corresponding replication-defective vectors. In this Exploration Award, we propose to test the concept that an oncolytic adenovirus can be armed with a therapeutic gene that will exert a systemic effect in the treatment of breast cancer. Breast cancer most commonly metastasizes to the skeleton. Thus, a treatment that combines eradication of the primary tumor with inhibition of osteolytic bone metastases would be a highly beneficial addition to the therapeutic armamentarium. We have previously shown that osteoprotegerin (OPG) can inhibit osteolytic bone metastases in a murine model. We hypothesize that an oncolytic adenovirus armed with the OPG gene would be able to eradicate a primary breast cancer tumor by oncolysis, and that secretion of OPG from the infected and lysed cells into the systemic circulation would inhibit osteolytic bone metastases of the breast cancer. Thus, we propose a new class of therapeutic agent for the treatment of breast cancer. The ability of the OPG-Fc secreted by infected cells to bind its cognate ligand, receptor activator of nuclear factor kappaB ligand (RANKL) was confirmed in a pull-down assay (Fig. 2 ).
BODY
Primary Ab: Anti-OPG Evaluation of the efficacy of the armed replicating adenoviral vector in vitro a.
Perform in vitro experiments to determine oncolytic potency.
b.
Perform in vitro experiments to determine expression of OPG.
Monolayers of MDA-MB-231 breast cancer cells were infected with a wild-type adenovirus (Ad300wt) plus the AdOPG vector, with the wild-type adenovirus alone, or with the AdOPG vector alone. We wished to confirm that expression of OPG does not inhibit the oncolytic potency of the replicating adenovirus. Hence, we measured the level of adenoviral DNA (Fig. 3) , and performed both qualitative (Fig. 4) and quantitative (Fig. 5) assays of the numbers of viable cells eight days post-infection of the cells at a low multiplicity of infection (MOI). These assays confirmed that expression of OPG does not inhibit the oncolytic potency of the replicating adenovirus.
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Z< IIAdOPG MOI 0 Z 1400000 Q *AdOPG MOI I 1200000 r-OAdOPG MOI 10 S1000000 IAdOPG MOI 100 0O "C 800000 Having completed the first two specific aims of the proposal, we are now initiating the third specific aim, to evaluate the efficacy of the armed replicating adenoviral vector in vivo. . A dual-action armed replicating adenovirus for the treatment of bone metastases of breast cancer. Molecular Therapy 9(S 1): S370, #968. * The data generated in the work supported by this award form the basis of an application for an ROI from the NIH.
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CONCLUSIONS
We have performed preliminary experiments to explore the concept that a replicationselective adenovirus armed with the OPG gene could both eradicate primary breast cancer tumors by oncolysis and inhibit osteolytic bone metastases of breast cancer. While the final form of this novel therapeutic agent will be a single virus, a breast cancer-selective replicating adenovirus carrying the OPG gene, we have employed a two-component model system in these proof-of-concept studies. In this regard, coinfection of cells with a wild-type adenovirus and a replication-defective El-deleted adenoviral vector expressing OPG allows replication of the vector as a result of trans-complementation by the viral El proteins expressed by the wild-type virus.
We first constructed a replication-defective adenoviral vector expressing human OPG fused with the Fc domain of human IgG to prolong its half-life in the bloodstream. It is important that the expression of OPG should not impair the oncolytic potency of the replicating adenovirus in breast cancer cells. In addition, we wish to confirm that a greater level of OPG will be expressed by a replicating virus than by a replication-defective adenoviral vector. Hence, we perform in vitro studies to confirmed these two key indicators of the efficacy of the novel therapeutic agent. We will now determine whether the armed replicating adenoviral vector can treat primary and metastatic breast cancer in a murine model.
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